We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted fast track designation to ...

The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line ...

July 1 (Reuters) - IPSEN SA: * IPSEN PRESENTS PHASE I/II CLINICAL DATA EVALUATING LIPOSOMAL IRINOTECAN (ONIVYDE®) AS AN INVESTIGATIONAL FIRST-LINE COMBINATION TREATMENT FOR METASTATIC PANCREATIC ...

SAN FRANCISCO -- A four-drug chemotherapy combination coaxed a statistically significant 2-month improvement in overall survival (OS) in untreated metastatic pancreatic cancer versus a ...

Germline and somatic DNA damage repair gene mutations potentially predict the efficacy of relevant treatment in Chinese patients with pancreatic ductal adenocarcinoma. This is an ASCO Meeting Abstract ...

Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan + 5-fluorouracil/leucovorin (5-FU/LV ...

Please provide your email address to receive an email when new articles are posted on . Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has completed its acquisition of global oncology assets from Merrimack Pharmaceuticals, in Cambridge, ...

The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). Patients with SCLC and progression on or after first-line ...

PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for ...

The novel pegylated liposomal formulation of irinotecan (formerly known as MM-398, marketed as Onivyde by Shire Pharmaceuticals, licensed from Merrimak) has been recommended for approval in the ...